newsfilter
← Latest News
ACCESS Newswire·

Integrated BioPharma Reports Results for its Quarter Ended September 30, 2026

  • Integrated BioPharma reported revenue of $9.9 million for the quarter ended September 30, 2026, a 22% decrease from $12.7 million in the same period in 2025.
  • The company recorded an operating loss of $0.96 million for the quarter ended September 30, 2026, compared to operating income of $0.16 million in 2025.
  • Net loss for the quarter ended September 30, 2026, was $0.69 million, whereas the company reported a net income of $0.12 million in 2025.
  • Diluted net loss per share was $(0.02) for the quarter ended September 30, 2026, compared to $0.00 per share in 2025.
  • Revenue from the two largest customers in the Contract Manufacturing Segment represented approximately 88% of total revenue for the quarter ended September 30, 2026.
  • Gross profit turned into a loss of $0.112 million for the quarter ended September 30, 2026, down from a gross profit of $1.019 million in 2025.
  • Selling and administrative expenses were $0.849 million for the quarter ended September 30, 2026, slightly down from $0.856 million in 2025.
  • Integrated BioPharma is engaged in the manufacturing, distribution, marketing, and sales of vitamins, nutritional supplements, and herbal products.
Company
Integrated BioPharma, Inc.
Keywords
Healthcare & Pharmaceutical, Earnings